Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes

Arkema, A.; Huckriede, Anke; Schoen, Pieter; Wilschut, Jan; Daemen, Toos

doi:10.1016/s0264-410x(99)00404-1

Cited by 71 publications

(28 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32,33 (A Huckriede, unpublished observations). However, this process of passive encapsulation is rather inefficient as the encapsulated volume is small as compared to the total volume of the suspension.…”

Section: Generation Of Virosomesmentioning

confidence: 98%

“…They get access to the MHC class II as well as the MHC class I presentation route indicating uptake of the virosomes by endocytosis and fusion of the virosomal and the endosomal membrane. [32][33][34] In order to allow for delivery of plasmid DNA, cationic lipids can be added to the solubilized membrane components prior to reconstitution and are incorporated into the virosomal membrane. Virosomes modified in this manner bind exogenously added DNA with high affinity and transfect cells efficiently.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs

et al. 2005

View full text Add to dashboard Cite

Section: Generation Of Virosomesmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs

et al. 2005

View full text Add to dashboard Cite

“…Strong cytotoxic T lymphocyte responses can be induced by peptides derived from the infl uenza nucleoprotein delivered by virosomes. All evidence indicated that the encapsulated peptides and proteins gained access to the cytoplasm (48,49).…”

Section: Application Of Virosomes As Drug Delivery Systemsmentioning

confidence: 99%

Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment

Liu

Feng

et al. 2015

Acta Pharmaceutica

View full text Add to dashboard Cite

A virosome is an innovative hybrid drug delivery system with advantages of both viral and non-viral vectors. Studies have shown that a virosome can carry various biologically active molecules, such as nucleic acids, peptides, proteins and small organic molecules. Targeted drug delivery using virosome-based systems can be achieved through surface modifi cations of virosomes. A number of virosome--based prophylactic and therapeutic products with high safety profi les are currently available in the market. Cancer treatment is a big ba lefi eld for virosome-based drug delivery systems. This review provides an overview of the general concept, preparation procedures, working mechanisms, preclinical studies and clinical applications of virosomes in cancer treatment.

show abstract

“…Virosomes are devoid of viral nucleoproteins, but during their preparation, antigens can be encapsulated into the CIRIV and thus, like viral genome, could be released into the cytosol of APC. This leads to their presentation in association with MHC class I molecules, and therefore to induction of CD8+ T cells (8)(9)(10). In addition to their capacity to deliver compounds into the cytosol of target cells, virosomes physically protect soluble antigens from extracellular protease degradation (11,12).…”

Section: Introductionmentioning

confidence: 99%

Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells

Angel

Chaperot

Molens

et al. 2007

Vaccine

View full text Add to dashboard Cite

Cytotoxic T lymphocytes (CTL) are crucial in viral clearance and tumor growth control. Thus the induction of CTL activity is an important aim in vaccine development. We investigate an innovative delivery system for peptide transfer to the MHC class-I processing pathway of APC with the aim to trigger CTL in the context of an anti-tumoral response. The strategy relies on a novel antigen delivery system termed "chimeric immunopotentiating reconstituted influenza virosomes" (CIRIV) targeting plasmacytoid dendritic cells (PDC). By using virosomes containing encapsulated Melan-A peptide and a PDC line developed in our laboratory, we evaluated the response of Melan-A specific T cells. Virosomes have the capacity to bind PDC and are endocyted within vesicles in the cytosol. This endocytosis is inhibited by neuraminidase, suggesting that it is mediated by sialic acid present on cell surface. Furthermore, PDC loaded with Melan-A virosomes can induce a Melan-A specific T cell activation. Interestingly, they activate T cells with a better efficiency than PDC loaded with a free peptide and when PDC where previously activated by a TLR ligand. These results indicate that virosomes could be a suitable delivery system for tumor peptide in immunotherapy of cancer.

show abstract

Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes

Cited by 71 publications

References 34 publications

Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs

Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs

Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment

Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells

Contact Info

Product

Resources

About